Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097 | 0.85 | ESR1 (0.41) | HDAC8HDAC6CYP1A2SLC6A2MMP12 | |
| SCHEMBL5807 | 0.79 | F2 (0.40) | — | |
| SCHEMBL11889 | 0.77 | POLB (0.41) | PKM | |
| SCHEMBL5511 | 0.76 | CASP1 (0.32) | SLC6A2MMP12MMP13 | |
| SCHEMBL15957862 | 0.73 | HDAC8 (0.44) | HDAC8HDAC6GRIA4CYP2C9HSD17B10 | |
| SCHEMBL13383171 | 0.72 | CYP1A2 (0.38) | FPR2HDAC8HDAC6GRIA4CYP1A2 | |
| SCHEMBL21773927 | 0.72 | FFAR1 (0.52) | HDAC8HDAC6CYP1A2CYP2C9 | |
| SCHEMBL21773925 | 0.72 | FFAR1 (0.52) | HDAC8HDAC6CYP1A2CYP2C9 | |
| SCHEMBL5656 | 0.70 | SLC6A2 (0.58) | SLC6A2MMP12MMP13 | |
| SCHEMBL10999 | 0.70 | SLC6A2 (0.58) | SLC6A2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | FPR2 841/4885HDAC8 67/4885HDAC6 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.